Inhibitors of ERK1/2 pathway has also been shown to enhance apoptosis caused by other microtubule-interfering agents already being used in cancer therapy, and the combinations are suggested to represent a new anticancer strategy, requiring lower drug dosages compared to drug monotherapy and may enhance tumor suppression in vivo (Zelivianski et al, 2003). The gene discussed is MAPK3; the disease is cancer.